Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Neuroinflammation
Published in: Journal of Neuroinflammation 1/2016

Open Access 01-12-2016 | Research

Aqueous extract from the Withania somnifera leaves as a potential anti-neuroinflammatory agent: a mechanistic study

Authors: Muskan Gupta, Gurcharan Kaur

Published in: Journal of Neuroinflammation | Issue 1/2016

Login to get access

Abstract

Background

Microglial-mediated neuroinflammation is a key factor underlying the pathogenesis of various neurodegenerative diseases and also an important target for the development of the neuroinflammation-targeted therapeutics. Conventionally, the nonsteroidal anti-inflammatory drugs (NSAIDs) are prescribed, but they are associated with long-term potential risks. Natural products are the cornerstone of modern therapeutics, and Ashwagandha is one such plant which is well known for its immunomodulatory properties in Ayurveda.

Methods

The current study was aimed to investigate the anti-neuroinflammatory potential of Ashwagandha (Withania somnifera) leaf water extract (ASH-WEX) and one of its active chloroform fraction (fraction IV (FIV)) using β-amyloid and lipopolysaccharide (LPS)-stimulated primary microglial cells and BV-2 microglial cell line. Iba-1 and α-tubulin immunocytochemistry was done to study the LPS- and β-amyloid-induced morphological changes in microglial cells. Inflammatory molecules (NFkB, AP1), oxidative stress proteins (HSP 70, mortalin), apoptotic markers (Bcl-xl, PARP), cell cycle regulatory proteins (PCNA, Cyclin D1), and MHC II expression were analyzed by Western blotting. Mitotracker and CellRox Staining, Sandwich ELISA, and Gelatin Zymography were done to investigate ROS, pro-inflammatory cytokines, and matrix metalloproteinase production, respectively. Ashwagandha effect on microglial proliferation, migration, and its apoptosis-inducing potential was studied by cell cycle analysis, migration assay, and Annexin-V FITC assay, respectively.

Results

ASH-WEX and FIV pretreatment was seen to suppress the proliferation of activated microglia by causing cell cycle arrest at Go/G1 and G2/M phase along with decrease in cell cycle regulatory protein expression such as PCNA and Cyclin D1. Inhibition of microglial activation was revealed by their morphology and downregulated expression of microglial activation markers like MHC II and Iba-1. Both the extracts attenuated the TNF-α, IL-1β, IL-6, RNS, and ROS production via downregulating the expression of inflammatory proteins like NFkB and AP1. ASH-WEX and FIV also restricted the migration of activated microglia by downregulating metalloproteinase expression. Controlled proliferation rate was also accompanied by apoptosis of activated microglia. ASH-WEX and FIV were screened and found to possess Withaferin A and Withanone as active phytochemicals.

Conclusions

The current data suggests that ASH-WEX and FIV inhibit microglial activation and migration and may prove to be a potential therapeutic candidate for the suppression of neuroinflammation in the treatment of neurodegenerative diseases.
Literature
1.
Block ML, Hong JS. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol. 2005;76:77–98.CrossRefPubMed
2.
Saijo K, Glass CK. Microglial cell origin and phenotypes in health and disease. Nat Rev Immunol. 2011;11:775–87.CrossRefPubMed
3.
Rock RB, Peterson PK. Microglia as a pharmacological target in infectious and inflammatory diseases of the brain. J Neuroimmune Pharmacol. 2006;1:117–26.CrossRefPubMed
4.
Glezer I, Simard AR, Rivest S. Neuroprotective role of the innate immune system by microglia. Neuroscience. 2007;147:867–83.CrossRefPubMed
5.
Liu B, Hong JS. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharm Exp Ther. 2003;304:1–7.CrossRef
6.
Ajmone-Cat MA, Bernardo A, Greco A, Minghetti L. Non-steroidal anti-inflammatory drugs and brain inflammation: effects on microglial functions. Pharmaceuticals. 2010;3:1949–65.CrossRefPubMedCentral
7.
Asanuma M, Nishibayashi‐Asanuma S, Miyazaki I, Kohno M, Ogawa N. Neuroprotective effects of non‐steroidal anti‐inflammatory drugs by direct scavenging of nitric oxide radicals. J Neurochem. 2001;76:1895–904.CrossRefPubMed
8.
Choi DK, Koppula S, Suk K. Inhibitors of microglial neurotoxicity: focus on natural products. Molecules. 2011;16:1021–43.CrossRefPubMed
9.
Li R, Huang YG, Fang D, Le WD. (−)‐Epigallocatechin gallate inhibits lipopolysaccharide‐induced microglial activation and protects against inflammation‐mediated dopaminergic neuronal injury. J Neurosci Res. 2004;78:723–31.CrossRefPubMed
10.
Renaud J, Martinoli MG. Resveratrol as a protective molecule for neuroinflammation: a review of mechanisms. Curr Pharm Biotechnol. 2014;15:318–29.CrossRefPubMed
11.
Zhong LM, Zong Y, Sun L, Guo JZ, Zhang W, He Y, et al. Resveratrol inhibits inflammatory responses via the mammalian target of rapamycin signaling pathway in cultured LPS-stimulated microglial cells. PloS One. 2012. doi:10.​1371/​journal.​pone.​0032195.
12.
Mishra LC, Singh BB, Dagenais S. Scientific basis for the therapeutic use of Withania somnifera (Ashwagandha): a review. Altern Med Rev. 2000;5:334–46.PubMed
13.
Uddin Q, Samiulla L, Singh VK, Jamil SS. Phytochemical and pharmacological profile of Withania somnifera Dunal: a review. J Appl Pharm Sci. 2012;2:170–5.
14.
Kumar S, Harris RJ, Seal CJ, Okello EJ. An aqueous extract of Withania somnifera root inhibits amyloid β fibril formation in vitro. Phytother Res. 2012;26:113–7.CrossRefPubMed
15.
Matsuda H, Murakami T, Kishi A, Yoshikawa M. Structures of withanosides I, II, III, IV, V, VI, and VII, new withanolide glycosides, from the roots of Indian Withania somnifera DUNAL. and inhibitory activity for tachyphylaxis to clonidine in isolated guinea-pig ileum. Bioorg Med Chem. 2001;9:1499–507.CrossRefPubMed
16.
Grover A, Shandilya A, Punetha A, Bisaria VS, Sundar D. Inhibition of the NEMO/IKKβ association complex formation, a novel mechanism associated with the NF-kB activation suppression by Withania somnifera’s key metabolite withaferin A. BMC Genomics. 2010;11 Suppl 4:S25.CrossRefPubMed
17.
Kaileh M, Berghe WV, Heyerick A, Horion J, Piette J, Libert C, et al. Withaferin A strongly elicits IkB kinase β hyperphosphorylation concomitant with potent inhibition of its kinase activity. J Bio Chem. 2007;282:4253–64.CrossRef
18.
Min KJ, Choi K, Kwon TK. Withaferin A down-regulates lipopolysaccharide-induced cyclooxygenase-2 expression and PGE2 production through the inhibition of STAT1/3 activation in microglial cells. Int Immunopharmacol. 2011;11:1137–42.CrossRefPubMed
19.
20.
Kataria H, Wadhwa R, Kaul SC, Kaur G. Withania somnifera water extract as a potential candidate for differentiation based therapy of human neuroblastomas. PLoS One. 2013;2013:8.
21.
22.
Kataria H, Wadhwa R, Kaul SC, Kaur G. Water extract from the leaves of Withania somnifera protects RA differentiated C6 and IMR-32 cells against glutamate-induced excitotoxicity. PloS One. 2012. doi:10.​1371/​journal.​pone.​0037080.
23.
Amura CR, Kamei T, Ito N, Soares MJ, Morrison DC. Differential regulation of lipopolysaccharide (LPS) activation pathways in mouse macrophages by LPS-binding proteins. J Immunol. 1998;161:2552–60.PubMed
24.
Cai Z, Hussain MD, Yan LJ. Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer’s disease. Int J Neurosci. 2014;124:307–21.CrossRefPubMed
25.
Saura J, Tusell JM, Serratosa J. High‐yield isolation of murine microglia by mild trypsinization. Glia. 2003;44:183–9.CrossRefPubMed
26.
Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods. 1989;119:203–10.CrossRefPubMed
27.
Stence N, Waite M, Dailey ME. Dynamics of microglial activation: a confocal time‐lapse analysis in hippocampal slices. Glia. 2001;33:256–66.CrossRefPubMed
28.
Gonzalez H, Elgueta D, Montoya A, Pacheco R. Neuroimmune regulation of microglial activity involved in neuroinflammation and neurodegenerative diseases. J Neuroimmunol. 2014;274:1–13.CrossRefPubMed
29.
Ohsawa K, Imai Y, Kanazawa H, Sasaki Y, Kohsaka S. Involvement of Iba1 in membrane ruffling and phagocytosis of macrophages/microglia. J Cell Sci. 2000;113:3073–84.PubMed
30.
Chiurchiu V, Maccarrone M. Chronic inflammatory disorders and their redox control: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal. 2011;15:2605–41.CrossRefPubMed
31.
Qian L, Tan KS, Wei SJ, Wu HM, Xu Z, Wilson B, et al. Microglia-mediated neurotoxicity is inhibited by morphine through an opioid receptor-independent reduction of NADPH oxidase activity. J Immunol. 2007;179:1198–209.CrossRefPubMed
32.
Dawson VL, Dawson TM, Bartley DA, Uhl GR, Snyder SH. Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures. J Neurosci. 1993;13:2651–61.PubMed
33.
RajaSankar S, Manivasagam T, Surendran S. Ashwagandha leaf extract: a potential agent in treating oxidative damage and physiological abnormalities seen in a mouse model of Parkinson’s disease. Neurosci Lett. 2009;454:11–5.CrossRefPubMed
34.
Liu Y, Liu W, Song XD, Zuo J. Effect of GRP75/mthsp70/PBP74/mortalin overexpression on intracellular ATP level, mitochondrial membrane potential and ROS accumulation following glucose deprivation in PC12 cells. Mol Cell Biochem. 2005;268:45–51.CrossRefPubMed
35.
Xu L, Voloboueva LA, Ouyang Y, Emery JF, Giffard RG. Overexpression of mitochondrial Hsp70/Hsp75 in rat brain protects mitochondria, reduces oxidative stress, and protects from focal ischemia. J Cereb Blood Flow Metab. 2009;29:365–74.CrossRefPubMed
36.
Dokladny K, Lobb R, Wharton W, Ma TY, Moseley PL. LPS-induced cytokine levels are repressed by elevated expression of HSP70 in rats: possible role of NF-kB. Cell Stress Chaperon. 2010;15:153–63.CrossRef
37.
Nam KN, Son MS, Park JH, Lee EH. Shikonins attenuate microglial inflammatory responses by inhibition of ERK, Akt, and NF-kB: neuroprotective implications. Neuropharmacology. 2008;55:819–25.CrossRefPubMed
38.
McCoy MK, Martinez TN, Ruhn KA, Szymkowski DE, Smith CG, Botterman BR, et al. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson’s disease. J Neurosci. 2006;26:9365–75.CrossRefPubMedPubMedCentral
39.
Teismann P, Ferger B. Inhibition of the cyclooxygenase isoenzymes COX‐1 and COX‐2 provide neuroprotection in the MPTP‐mouse model of Parkinson’s disease. Synapse. 2001;39:167–74.CrossRefPubMed
40.
Wang T, Qin L, Liu B, Liu Y, Wilson B, Eling TE, et al. Role of reactive oxygen species in LPS‐induced production of prostaglandin E2 in microglia. J Neurochem. 2004;88:939–47.CrossRefPubMed
41.
42.
Jeohn GH, Kong LY, Wilson B, Hudson P, Hong JS. Synergistic neurotoxic effects of combined treatments with cytokines in murine primary mixed neuron/glia cultures. J Neuroimmunol. 1998;85:1–10.CrossRefPubMed
43.
Oh JH, Lee TJ, Park JW, Kwon TK. Withaferin A inhibits iNOS expression and nitric oxide production by Akt inactivation and down-regulating LPS-induced activity of NF-kB in RAW 264.7 cells. Eur J Pharmacol. 2008;599:11–7.CrossRefPubMed
44.
Leiro J, Arranz JA, Yanez M, Ubeira FM, Sanmartın ML, Orallo F. Expression profiles of genes involved in the mouse nuclear factor-kappa B signal transduction pathway are modulated by mangiferin. Int Immunopharmacol. 2004;4:763–78.CrossRefPubMed
45.
Moon DO, Park SY, Lee KJ, Heo MS, Kim KC, Kim MO, et al. Bee venom and melittin reduce proinflammatory mediators in lipopolysaccharide-stimulated BV-2 microglia. Int Immunopharmacol. 2007;7:1092–101.CrossRefPubMed
46.
Sivamani S, Joseph B, Kar B. Anti-inflammatory activity of Withania somnifera leaf extract in stainless steel implant induced inflammation in adult zebrafish. J Genet Eng Biotechn. 2014;12:1–6.CrossRef
47.
Maitra R, Porter MA, Huang S, Gilmour BP. Inhibition of NFkappaB by the natural product Withaferin A in cellular models of cystic fibrosis inflammation. Inflamm (Lond). 2009;6:15.CrossRef
48.
Borsello T, Forloni G. JNK signalling: a possible target to prevent neurodegeneration. Curr Pharm Des. 2007;13:1875–86.CrossRefPubMed
49.
Jang S, Kelley KW, Johnson RW. Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proc Natl Acad Sci U S A. 2008;105:7534–9.CrossRefPubMedPubMedCentral
50.
51.
Fujioka S, Niu J, Schmidt C, Sclabas GM, Peng B, Uwagawa T, et al. NF-kB and AP-1 connection: mechanism of NF-kB-dependent regulation of AP-1 activity. Mol Cell Biol. 2004;24:7806–19.CrossRefPubMedPubMedCentral
52.
Kang G, Kong PJ, Yuh YJ, Lim SY, Yim SV, Chun W, et al. Curcumin suppresses lipopolysaccharide-induced cyclooxygenase-2 expression by inhibiting activator protein 1 and nuclear factor. kappa. b bindings in BV2 microglial cells. J Pharmacol Sci. 2004;94:325–8.CrossRefPubMed
53.
Yang X, Du L, Tang X, Jung SY, Zheng B, Soh BY, et al. Brevicompanine E reduces lipopolysaccharide-induced production of proinflammatory cytokines and enzymes in microglia by inhibiting activation of activator protein-1 and nuclear factor-kB. J Neuroimmunol. 2009;216:32–8.CrossRefPubMed
54.
Yuan L, Wu Y, Ren X, Liu Q, Wang J, Liu X. Isoorientin attenuates lipopolysaccharide-induced pro-inflammatory responses through down-regulation of ROS-related MAPK/NF-kB signaling pathway in BV-2 microglia. Mol Cell Biochem. 2014;386:153–65.CrossRefPubMed
55.
56.
Fukao T, Koyasu S. PI3K and negative regulation of TLR signaling. Trends Immunol. 2003;24:358–63.CrossRefPubMed
57.
De Oliveira AC, Candelario-Jalil E, Langbein J, Wendeburg L, Bhatia HS, Schlachetzki JC, et al. Pharmacological inhibition of Akt and downstream pathways modulates the expression of COX-2 and mPGES-1 in activated microglia. J Neuroinflammation. 2012. doi:10.​1186/​1742-2094-9-2.
58.
Huttmann K, Sadgrove M, Wallraff A, Hinterkeuser S, Kirchhoff F, Steinhauser C, et al. Seizures preferentially stimulate proliferation of radial glia‐like astrocytes in the adult dentate gyrus: functional and immunocytochemical analysis. Eur J Neurosci. 2003;18:2769–78.CrossRefPubMed
59.
Karlstetter M, Lippe E, Walczak Y, Moehle C, Aslanidis A, Mirza M, et al. Curcumin is a potent modulator of microglial gene expression and migration. J Neuroinflammation. 2011;8:125.CrossRefPubMedPubMedCentral
60.
Drache B, Diehl GE, Beyreuther K, Perlmutter LS, Konig G. Bcl‐xl‐Specific antibody labels activated microglia associated with Alzheimer’s disease and other pathological states. J Neurosci Res. 1997;47:98–108.CrossRefPubMed
61.
Elsisi NS, Darling-Reed S, Lee EY, Oriaku ET, Soliman KF. Ibuprofen and apigenin induce apoptosis and cell cycle arrest in activated microglia. Neurosci Lett. 2005;375:91–6.CrossRefPubMed
62.
63.
Lively S, Schlichter LC. The microglial activation state regulates migration and roles of matrix-dissolving enzymes for invasion. J Neuroinflammation. 2013;10:1186.CrossRef
Metadata
Title
Aqueous extract from the Withania somnifera leaves as a potential anti-neuroinflammatory agent: a mechanistic study
Authors
Muskan Gupta
Gurcharan Kaur
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2016
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/s12974-016-0650-3

Other articles of this Issue 1/2016

Journal of Neuroinflammation 1/2016 Go to the issue

Research

Interleukin-1β has trophic effects in microglia and its release is mediated by P2X7R pore

Research

The immunomodulator decoy receptor 3 improves locomotor functional recovery after spinal cord injury

Research

Andrographolide induces Nrf2 and heme oxygenase 1 in astrocytes by activating p38 MAPK and ERK

Research

Role of transient receptor potential ankyrin 1 channels in Alzheimer’s disease

Research

Differential expression of P2X7 receptor and IL-1β in nociceptive and neuropathic pain

Research

Sustained TNF production by central nervous system infiltrating macrophages promotes progressive autoimmune encephalomyelitis